Home News Info Guidelines Trials EUHASS Travel Products Organisations Genes QC FAQs About Links

Clinical Trials

Below is a list of active clinical trials worldwide which involve patients with inherited bleeding disorders. The link from each study title will take you to ClinicalTrials.gov which gives you more information about the trial.
To see a list of trials for a particular bleeding disorder use the drop-down list below to select the condition you're interested in. A new window will open up with a list of trials for this condition only.

Please select the category:
Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
Condition:   Haemophilia
Interventions:   Diagnostic Test: Thrombophilia screen;   Diagnostic Test: Initiation pathway analysis
Sponsor:   Royal Free Hospital NHS Foundation Trust
Recruiting
Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
Condition:   Von Willebrand Disease
Intervention:   Other: Non interventional study
Sponsor:   Nantes University Hospital
Recruiting
UK - EHL Outcomes Registry
Conditions:   Hemophilia A;   Hemophilia B
Intervention:  
Sponsor:   Royal Free Hospital NHS Foundation Trust
Recruiting
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Condition:   Glanzmann Thrombasthenia
Intervention:  
Sponsors:   Rockefeller University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Conditions:   Blood Coagulation Disorders, Inherited;   Thrombotic Disorder
Intervention:  
Sponsor:   The University of Texas Health Science Center, Houston
Recruiting
Platelet Glycoproteins in Inherited Thrombocytopathy: Association With Aggregation Studies and Bleeding Severity
Conditions:   Bleeding;   Platelet Dysfunction
Intervention:   Diagnostic Test: Flowcytometry analysis of platelets surface receptors
Sponsor:   Assiut University
Recruiting
REAL-LIFE DATA OF CONSTITUTIONAL VON WILLEBRAND DISEASE IN WESTERN FRANCE (HOPSCOTcH-WILL)
Condition:   Von Willebrand Diseases
Intervention:   Other: VWD treatments
Sponsors:   Nantes University Hospital;   CHU de Brest;   University Hospital, Angers;   CH Le Mans;   Rennes University Hospital
Not yet recruiting
Real World Study of Deep Venous Thrombosis. Analysis of Prospective Cases in University Hospitals of São Paulo
Condition:   Registry
Intervention:   Other: deep venous thrombosis
Sponsors:   Fundação Faculdade Regional de Medicina de São José do Rio Preto;   University of Ribeirao Preto
Recruiting
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Condition:   Hereditary Hemorrhagic Telangiectasia
Intervention:  
Sponsors:   St. Michael's Hospital, Toronto;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting
Evaluation of Patients With Immune Function Abnormalities
Conditions:   Immune System Diseases;   Chronic Granulomatous Disease (CGD);   X-Linked Severe Combined Immune Deficiency (XSCID);   Leukocyte Adhesion Deficiency 1 (LAD);   Graft Versus Host Disease (cGvHD)
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease.
Condition:   Hereditary Hemorrhagic Telangiectasia
Interventions:   Other: Phase 1 : fill out 1 scale;   Other: Phase 2 : fill out 1 scale and 4 questionnaires
Sponsor:   Hospices Civils de Lyon
Not yet recruiting
BAX 111 rVWF in Pediatrics
Condition:   Von Willebrand Disease
Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant)
Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
Recruiting
Investigation of the Genetics of Hematologic Diseases
Conditions:   Bone Marrow Failure Syndromes;   Erythrocyte Disorder;   Leukocyte Disorder;   Hemostasis;   Blood Coagulation Disorder;   Sickle Cell Disease;   Dyskeratosis Congenita;   Diamond-Blackfan Anemia;   Congenital Thrombocytopenia;   Severe Congenital Neutropenia;   Fanconi Anemia
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   Boston Children’s Hospital;   Baylor College of Medicine;   University of Memphis
Recruiting
World Bleeding Disorders Registry
Conditions:   Hemophilia A;   Hemophilia B
Intervention:  
Sponsor:   World Federation of Hemophilia
Not yet recruiting
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Osler Weber Rendu Disease
Interventions:   Drug: Propranolol treatment;   Drug: Placebo
Sponsors:   University Hospital, Bordeaux;   AMRO-HHT-France - Association Maladie de Rendu-Osler
Not yet recruiting
Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery
Condition:   Factor 10 Deficiency
Intervention:   Drug: Coagadex
Sponsor:   Bio Products Laboratory
Recruiting
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors
Conditions:   Adeno-Associated Virus (AAV);   Blood Coagulation Disorder;   Blood Coagulation Disorders, Inherited;   Coagulation Protein Disorders;   Factor VIII (FVIII);   Factor VIII (FVIII) Deficiency;   Factor VIII (FVIII) Gene;   Factor VIII (FVIII) Protein;   Genetic Diseases, Inborn;   Genetic Diseases, X-Linked;   Gene Therapy;   Gene Transfer;   Hematologic Diseases;   Hemorrhagic Disorders;   Recombinant;   Vector;   Inhibitors
Intervention:   Genetic: SPK-8016
Sponsor:   Spark Therapeutics
Recruiting
Doxycycline for Hereditary Hemorrhagic Telangiectasia
Condition:   Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions:   Drug: Doxycycline Hyclate;   Drug: Placebo
Sponsors:   St. Michael's Hospital, Toronto;   Barrow Neurological Institute;   Duke University;   Feinstein Institute for Medical Research;   University of Pittsburgh;   Sunnybrook Health Sciences Centre
Recruiting
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Conditions:   Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Hemophilia A
Intervention:   Drug: Emicizumab
Sponsor:   Hoffmann-La Roche
Not yet recruiting
Swiss Hemophilia Registry
Condition:   Hemophilia and Other Severe Bleeding Disorders
Intervention:   Other: Registry
Sponsor:   Swiss Hemophilia Network
Recruiting
Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
Condition:   Hereditary Hemorrhagic Telangiectasia
Interventions:   Biological: Blood samples;   Other: Epistaxis charts
Sponsor:   Centre Hospitalier Universitaire Dijon
Recruiting
Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Epistaxis Nosebleed;   Anemia
Interventions:   Drug: Pazopanib;   Drug: Placebo oral capsule
Sponsor:   Cure HHT
Not yet recruiting
Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia
Condition:   Hereditary Hemorrhagic Telangiectasia
Interventions:   Drug: Timolol Gel;   Drug: Placebo Gel
Sponsor:   Washington University School of Medicine
Recruiting
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
Conditions:   Blood Coagulation Disorder;   Blood Coagulation Disorders, Inherited;   Coagulation Protein Disorders;   Hemophilia A;   Genetic Diseases, Inborn;   Genetic Diseases, X-Linked;   Hematologic Diseases;   Hemorrhagic Disorders;   Factor VIII Deficiency
Intervention:   Drug: Standard of Care FVIII Replacement therapy
Sponsor:   Spark Therapeutics
Recruiting
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Conditions:   Thrombotic Thrombocytopenic Purpura;   Congenital Thrombotic Thrombocytopenic Purpura;   Familial Thrombotic Thrombocytopenic Purpura;   Thrombotic Thrombocytopenic Purpura, Congenital;   Upshaw-Schulman Syndrome
Intervention:   Other: Observation
Sponsors:   University Hospital Inselspital, Berne;   Swiss National Science Foundation;   Mach Gaensslen Foundation;   Baxalta Innovations GmbH, Wien, Austria
Recruiting
Vitamin D and Hereditary Haemorrhagic Telangiectasia
Condition:   Hereditary Haemorrhagic Telangiectasia
Interventions:   Drug: Vit D;   Drug: Placebo Oral Tablet
Sponsor:   St. Paul's Hospital, Canada
Recruiting
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Condition:   Telangiectasia, Hereditary Hemorrhagic
Intervention:  
Sponsors:   Imperial College London;   British Heart Foundation
Recruiting
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Idiopathic Vascular Ectasia
Intervention:   Drug: Pomalidomide
Sponsor:   The Cleveland Clinic
Recruiting
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Epistaxis
Intervention:   Drug: Pazopanib
Sponsors:   Cure HHT;   University of North Carolina
Not yet recruiting
Pregnancy and Fibrinogen Disorders
Conditions:   Hypofibrinogenemia, Congenital;   Afibrinogenemia, Congenital;   Dysfibrinogenemia, Congenital
Intervention:  
Sponsors:   University Hospital, Geneva;   Swiss Hemophilia Network
Recruiting
Pomalidomide for the Treatment of Bleeding in HHT
Condition:   Telangiectasia, Hereditary Hemorrhagic
Interventions:   Drug: Pomalidomide Oral Product;   Drug: Placebo oral capsule
Sponsors:   The Cleveland Clinic;   RTI International
Not yet recruiting
Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry
Conditions:   Hereditary Hemorrhagic Telangiectasia;   HHT;   Brain Arteriovenous Malformation (BAVM)
Intervention:   Other: Registry and Saliva sample
Sponsors:   St. Michael's Hospital, Toronto;   HHT Foundation International;   Dartmouth College
Recruiting
Evaluation of Video-assisted Instructions of Nasal Self-packing in Patients With HHT
Condition:   Hereditary Haemorrhagic Telangiectasia
Intervention:   Procedure: video-assisted nasal self-packing
Sponsor:   University Hospital, Essen
Recruiting
An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment
Conditions:   Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Haemophilia A
Intervention:   Drug: Standard of Care for Haemophilia A
Sponsor:   Hoffmann-La Roche
Not yet recruiting
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Conditions:   Hereditary Hemorrhagic Telangiectasia (HHT);   Epistaxis
Interventions:   Drug: Floseal;   Other: Packing
Sponsors:   St. Michael's Hospital, Toronto;   The Ottawa Hospital
Recruiting
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Conditions:   Cavernous Angioma, Familial;   Cerebral Cavernous Malformations;   Cerebral Cavernous Hemangioma
Intervention:  
Sponsors:   University of California, San Francisco;   University of New Mexico;   University of Chicago;   National Institute of Neurological Disorders and Stroke (NINDS);   Boston Children’s Hospital;   Children's Hospital Medical Center, Cincinnati;   Barrow Neurological Institute;   Angioma Alliance
Recruiting
A Gene Transfer Study for Hemophilia A
Condition:   Hemophilia A
Intervention:   Genetic: SPK-8011
Sponsor:   Spark Therapeutics
Recruiting
Low VW Activity in Adolescent HMB
Condition:   Von Willebrand Factor Deficiency
Interventions:   Other: Genetic Analysis;   Other: Medical Record Data Abstraction;   Other: Pictorial Blood Assessment Chart (PBAC) score;   Other: Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Shire
Recruiting
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Conditions:   Congenital Bleeding Disorder;   Haemophilia B
Intervention:   Drug: nonacog beta pegol
Sponsor:   Novo Nordisk A/S
Recruiting
Immunmodulation in Patients With HHT
Condition:   Hereditary Haemorrhagic Telangiectasia (HHT)
Intervention:   Other: blood sample
Sponsor:   University Hospital, Essen
Recruiting
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
Condition:   Severe Hemophilia A
Intervention:   Drug: OCTA101
Sponsor:   Octapharma
Recruiting
Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Dental Diseases
Intervention:  
Sponsors:   University Hospital, Essen;   Philipps University Marburg Medical Center;   University Hospital, Aachen;   German HHT self-help group
Not yet recruiting
Handheld Ultrasound (HHUS) for Home Use in Hemophilia
Conditions:   Joint Bleed;   Hemophilia A
Intervention:   Device: handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
Sponsors:   Bloodworks;   Genentech, Inc.
Not yet recruiting
Weight-based Dosing in Hemophilia A
Condition:   Hemophilia
Intervention:   Drug: rFVIII
Sponsor:   Craig Seaman
Recruiting
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
Conditions:   Hemophilia A;   Hemophilia B
Interventions:   Drug: fitusiran;   Drug: factor VIII or factor IX
Sponsor:   Genzyme, a Sanofi Company
Recruiting
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
Conditions:   Hemophilia A;   Hemophilia B
Interventions:   Drug: fitusiran;   Drug: recombinant Factor VIIa and FEIBA
Sponsor:   Genzyme, a Sanofi Company
Recruiting
Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia
Condition:   Thrombocytopenia
Intervention:   Drug: Eltrombopag
Sponsors:   University Hospital, Toulouse;   French network for inherited hemorragic diseases;   National Reference Centre for Platelet Pathologies
Recruiting
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
Condition:   Hemophilia A
Intervention:   Other: assessment of joint health and bone density
Sponsors:   Bloodworks;   Genentech, Inc.
Recruiting
Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
Condition:   Factor VII Deficiency
Interventions:   Biological: Eptacog alfa, biosimilar and reference medicinal product Novoseven;   Biological: Eptacog alfa biosimilar
Sponsor:   AryoGen Pharmed Co.
Recruiting
Ultrasonography in Hemophilic Joint Disease and Serum Markers
Conditions:   Hemophilia A;   Hemophilia B;   Hemarthroses
Intervention:   Other: ultrasound
Sponsors:   Northwell Health;   National Cancer Institute (NCI);   University of California, San Diego
Recruiting
Von Willebrand Disease in the Netherlands
Condition:   Von Willebrand Disease
Intervention:  
Sponsors:   Erasmus Medical Center;   Stichting Haemophilia (Dutch Haemophilia Foundation);   CSL Behring;   Shire
Not yet recruiting
Longitudinal Studies of Patient With FPDMM
Conditions:   Inherited Hematological Diseases;   Rare Diseases;   FPDMM
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Condition:   Hermansky-Pudlak Syndrome (HPS)
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
Conditions:   Adrenoleukodystrophy;   Batten Disease;   Mucopolysaccharidosis II;   Leukodystrophy, Globoid Cell;   Leukodystrophy, Metachromatic;   Neimann Pick Disease;   Pelizaeus-Merzbacher Disease;   Sandhoff Disease;   Tay-Sachs Disease;   Brain Diseases, Metabolic, Inborn;   Alpha-Mannosidosis;   Sanfilippo Mucopolysaccharidoses
Intervention:   Biological: DUOC-01
Sponsors:   Joanne Kurtzberg, MD;   The Marcus Foundation
Recruiting
A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt
Conditions:   Hemophilia;   Von Willebrand Diseases;   Christmas Disease
Intervention:  
Sponsor:   Safaa AA Khaled
Not yet recruiting
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Condition:   Hemophilia
Intervention:  
Sponsor:   Karolinska Institutet
Recruiting
A Factor IX Gene Therapy Study (FIX-GT)
Condition:   Hemophilia B
Intervention:   Biological: FLT180a
Sponsor:   University College, London
Recruiting
A Study of Haemophilia B Patients Who Have Undergone Gene Therapy
Condition:   Hemophilia B
Intervention:   Biological: FLT180a
Sponsor:   Freeline Therapeutics
Recruiting
TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia
Condition:   Haemophilia A
Intervention:   Other: Thrombin generation measurement.
Sponsor:   Hospices Civils de Lyon
Recruiting
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation)
Condition:   Hemophilia A
Intervention:   Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)
Sponsor:   Bayer
Recruiting
ATHN 2: Factor Switching Study
Condition:   Hemophilia
Interventions:   Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013;   Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Sponsors:   American Thrombosis and Hemostasis Network;   Shire;   CSL Behring;   Bioverativ Therapeutics Inc.;   Bayer
Recruiting
Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease
Condition:   Type 1 Von Willebrand Disease
Interventions:   Drug: recombinant von Willebrand factor;   Drug: tranexamic acid
Sponsors:   Margaret Ragni;   University of North Carolina;   Duke University
Recruiting
Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis
Conditions:   Pulmonary Fibrosis;   Healthy Volunteers;   Hermansky-Pudlak Syndrome (HPS)
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting
Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT
Condition:   Idiopathic Thrombocytopenic Purpura
Intervention:   Other: non interventional study
Sponsor:   Nantes University Hospital
Not yet recruiting
Intranasal Bevacizumab for HHT-Related Epistaxis
Conditions:   HHT;   Hereditary Hemorrhagic Telangiectasia;   Epistaxis;   Nose Bleeds;   Nasal Bleeding
Interventions:   Drug: Bevacizumab;   Drug: Placebo (Saline)
Sponsor:   Stanford University
Recruiting
A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13)
Condition:   Congenital Thrombotic Thrombocytopenic Purpura
Interventions:   Biological: BAX930;   Biological: Standard of care
Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
Recruiting
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Conditions:   All Diagnosed Health Conditions;   ADD/ADHD;   Alopecia Areata;   Ankylosing Spondylitis;   Asthma;   Atopic Dermatitis Eczema;   Beta Thalassemia;   Bipolar Disorder;   Breast Cancer;   Celiac Disease;   Cervical Cancer;   Chronic Inflammatory Demyelinating Polyneuropathy;   Chronic Kidney Diseases;   Chronic Obstructive Pulmonary Disease;   Colon Cancer;   Colorectal Cancer;   Crohn's Disease;   Cystic Fibrosis;   Depression;   Diabetes Mellitus;   Duchenne Muscular Dystrophy;   Endometriosis;   Epilepsy;   Facioscapulohumeral Muscular Dystrophy;   G6PD Deficiency;   General Anxiety Disorder;   Hepatitis B;   Hereditary Hemorrhagic Telangiectasia;   HIV/AIDS;   Human Papilloma Virus;   Huntington's Disease;   Idiopathic Thrombocytopenic Purpura;   Insomnia;   Kidney Cancer;   Leukemia;   Lung Cancer;   Lupus Nephritis;   Lymphoma;   Melanoma;   Multiple Myeloma;   Multiple Sclerosis;   Myositis;   Myotonic Dystrophy;   Ovarian Cancer;   Pancreatic Cancer;   Parkinson's Disease;   Polycystic Kidney Diseases;   Prostate Cancer;   Psoriasis;   Psoriatic Arthritis;   Rosacea;   Scleroderma;   Sickle Cell Anemia;   Sickle Cell Trait;   Sjogren's Syndrome;   Skin Cancer;   Spinal Muscular Atrophy;   Systemic Lupus Erythematosus;   Thrombotic Thrombocytopenic Purpura;   Trisomy 21;   Ulcerative Colitis
Intervention:  
Sponsor:   Sanguine Biosciences
Recruiting
Study of Chediak-Higashi Syndrome
Condition:   Chediak Higashi Syndrome
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting
Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases
Conditions:   Von Willebrand Diseases;   Glanzmann Thrombasthenia
Interventions:   Device: Sublingual videomicroscopy;   Biological: blood sample
Sponsor:   University Hospital, Lille
Not yet recruiting
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
Condition:   Hemophilia B
Intervention:   Drug: Alprolix
Sponsor:   Swedish Orphan Biovitrum
Recruiting
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Conditions:   Haemophilia A;   Haemophilia B
Interventions:   Drug: ELOCTA;   Drug: ALPROLIX
Sponsor:   Swedish Orphan Biovitrum
Recruiting
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Condition:   Von Willebrand Diseases
Intervention:   Drug: VWF-containing products
Sponsor:   Octapharma
Recruiting
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
Condition:   Hemophilia A
Intervention:   Drug: Antihemophilic Factor (Kovaltry, BAY81-8973)
Sponsors:   Bayer;   American Thrombosis and Hemostasis Network
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
Condition:   Hemorrhagic Hereditary Telangiectasia (HHT)
Interventions:   Drug: Bevacizumab;   Drug: sodium chloride 0.9%
Sponsor:   Hospices Civils de Lyon
Recruiting
BAX 802 in CHA With Inhibitors
Condition:   Hemophilia A
Intervention:   Biological: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)
Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
Recruiting
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Condition:   Hemophilia A, Congenital
Intervention:   Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Sponsor:   Bayer
Recruiting
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
Condition:   Hemophilia A
Intervention:   Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)
Sponsor:   Bayer
Recruiting
ATHN 7: Hemophilia Natural History Study
Conditions:   Hemophilia A With Inhibitor;   Haemophilia A Without Inhibitor;   Hemophilia B With Inhibitor;   Haemophilia B Without Inhibitor
Intervention:  
Sponsors:   American Thrombosis and Hemostasis Network;   Genentech, Inc.
Recruiting
rVWF IN PROPHYLAXIS
Condition:   Von Willebrand Disease
Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant)
Sponsor:   Baxalta now part of Shire
Recruiting
China Registry for Genetic / Metabolic Liver Diseases
Condition:   Genetic/Metabolic Liver Diseases
Intervention:   Drug: Standard of care
Sponsors:   Beijing Friendship Hospital;   Beijing YouAn Hospital;   Henan Provincial Hospital;   Beijing Ditan Hospital;   Hebei Medical University Third Hospital;   Peking University First Hospital;   Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital;   Nanfang Hospital of Southern Medical University;   Logistics University of Chinese People's Armed Police Forces;   Beijing Anzhen Hospital;   West China Second University Hospital of Sichuan University;   Jinshan Hospital of Fudan University;   Fudan University
Recruiting
Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B
Conditions:   Haemophilia A;   Haemophilia B
Intervention:  
Sponsor:   Swedish Orphan Biovitrum
Recruiting
Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
Condition:   Von Willebrand Diseases
Intervention:  
Sponsor:   University Hospital, Lille
Recruiting
ATHN 8: PUPs Matter Study
Conditions:   Hemophilia;   Hemophilia A;   Hemophilia B;   Hemophilia A With Inhibitor;   Hemophilia B With Inhibitor;   Haemophilia B Without Inhibitor;   Haemophilia A Without Inhibitor;   Haemophilia
Intervention:  
Sponsors:   American Thrombosis and Hemostasis Network;   CSL Behring;   Octapharma;   Takeda
Recruiting
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
Condition:   Hemophilia B
Intervention:   Genetic: AAV5-hFIXco-Padua
Sponsor:   UniQure Biopharma B.V.
Recruiting
rVWF Pediatric and Adult Study
Condition:   Von Willebrand Disease
Interventions:   Biological: rVWF;   Biological: rFVIII
Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
Recruiting
Effectiveness and Tolerability of Eqwilate in Real-life Conditions
Condition:   VWD - Von Willebrand's Disease
Intervention:   Biological: Eqwilate
Sponsor:   Octapharma
Not yet recruiting
Treatment of Hemophilia A Patients With FVIII Inhibitors
Condition:   Hemophilia A
Interventions:   Biological: Nuwiq;   Biological: Octanate;   Biological: Wilate;   Biological: Emicizumab;   Biological: Recombinant factor VIIa (rFVIIa);   Biological: Activated prothrombin complex concentrate (aPCC)
Sponsors:   Emory University;   Octapharma
Not yet recruiting
Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients
Conditions:   Thrombocytopenia;   Splenectomy
Intervention:   Procedure: splenectomy
Sponsor:   Zhang Lei
Recruiting
Evaluation of Bleeding Score in Egyptian Patients With vWD Type I and Correlate it With Laboratory Parameters
Condition:   Von Willebrand Disease, Type 1
Intervention:   Diagnostic Test: The von Willebrand Antigen level
Sponsor:   Assiut University
Not yet recruiting
Differences in Preparation for Small Bowel Capsule Endoscopy
Conditions:   Capsule Endoscopy;   Inflammatory Bowel Diseases;   Celiac Disease
Interventions:   Drug: Klean Prep;   Other: Clear liquids only
Sponsors:   Sheffield Teaching Hospitals NHS Foundation Trust;   Hotel Dieu Hospital
Recruiting
Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease
Conditions:   Inflammatory Bowel Diseases;   Von Willebrand Diseases
Intervention:   Diagnostic Test: von willebrand antigen and activity
Sponsor:   Assiut University
Not yet recruiting
ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
Condition:   Hemophilia A
Interventions:   Biological: ADVATE;   Biological: ADYNOVI
Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
Recruiting
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Condition:   Hemophilia B
Intervention:   Biological: rIX-FP
Sponsor:   CSL Behring
Recruiting
The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B
Condition:   Hemophilia
Interventions:   Other: Blood sample;   Other: Questionnaire;   Other: MRI-imaging;   Other: Physical examination
Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting
Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Conditions:   Von Willebrand Diseases;   Major Constitutional Thrombopathy;   Patient on Antiplatelet Drugs
Intervention:   Biological: Blood sampling
Sponsor:   Centre Hospitalier Universitaire Dijon
Recruiting
Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
Condition:   Acquired Hemophilia A
Interventions:   Drug: Steroid;   Drug: Rituximab;   Drug: Cyclophosphamide
Sponsors:   Zhang Lei;   Qilu Hospital of Shandong University;   Tianjin First Central Hospital;   The Second Affiliated Hospital of Kunming Medical University;   Henan Cancer Hospital
Recruiting
Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype
Condition:   Hemophilia B
Intervention:   Other: data collection
Sponsor:   Centre Hospitalier Universitaire Dijon
Not yet recruiting
The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B)
Conditions:   Hemophilia A;   Hemophilia B
Interventions:   Drug: SerpinPC;   Drug: Placebo
Sponsor:   ApcinteX Ltd
Recruiting
Quality of Life and Adjustment Among Siblings of Children and Adolescents With Severe Hemophilia
Condition:   Severe Haemophilia
Intervention:  
Sponsor:   Assistance Publique Hopitaux De Marseille
Not yet recruiting
Von Willebrand Factor Concentrate During ECMO Support
Condition:   Acquired Von Willebrand Disease
Interventions:   Drug: Von Willebrand Factor;   Drug: Saline Solution
Sponsors:   Tirol Kiniken GmbH;   LFB BIOMEDICAMENTS
Recruiting
Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia
Condition:   Haemophilia
Intervention:   Other: Patient questionnaire
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting
Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
Condition:   Hemophilia A
Intervention:   Drug: Recombinant Human Coagulation FVIII
Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recruiting
Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia
Condition:   Haemophilia
Intervention:   Other: EHL clotting factor
Sponsor:   Investigación en Hemofilia y Fisioterapia
Not yet recruiting
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
Condition:   Hemophilia A
Intervention:   Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)
Sponsor:   Bayer
Not yet recruiting
A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1)
Condition:   Factor VIII Deficiency
Intervention:   Drug: BIVV001
Sponsor:   Sanofi
Not yet recruiting
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis
Condition:   Hemophilia
Intervention:   Drug: Fitusiran
Sponsor:   Genzyme, a Sanofi Company
Recruiting
Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Condition:   Hemophilia A
Intervention:   Drug: Plasma-derived FVIII/VWF concentrate
Sponsors:   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico;   Sintesi Research Srl
Recruiting
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
Condition:   Hemophilia A
Intervention:   Drug: Recombinant Human Coagulation FVIII
Sponsor:   Sinocelltech Ltd.
Not yet recruiting
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
Condition:   Hemophilia A
Intervention:   Drug: Recombinant Human Coagulation FVIII
Sponsors:   Sinocelltech Ltd.;   Chinese Academy of Medical Sciences;   Parexel;   Q2 Solutions
Not yet recruiting
Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
Conditions:   Congenital Afibrinogenemia;   Congenital Hypofibrinogenemia
Intervention:   Biological: BT524 (fibrinogen concentrate from human plasma)
Sponsors:   Biotest;   ICON plc;   SYNLAB Analytics & Services Germany GmbH;   Phoenix Clinical Research;   Accovion GmbH
Recruiting